Congress Materials – European Society for Medical Oncology (ESMO 2025)
2025 European Society for Medical Oncology | Oct 17-21 | Berlin, Germany
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Amivantamab in Recurrent/Metastatic Head & Neck Squamous Cell Cancer (HNSCC) After Disease Progression on Checkpoint Inhibition and Chemotherapy: Results From the Phase 1b/2 OrigAMI-4 Study
Kevin J. Harrington, Ari J. Rosenberg, Muh-Hwa Yang, Jessica Geiger, Marc Oliva, Myung-Ju Ahn, Sun Min Lim, William Ince, Aarti Bhatia, Siddharth Sheth, Bhumsuk Keam, Robert Metcalf, Gaspar Molina, Joshua C. Curtin, John Xie, Mark Wade, Emrullah Yilmaz, Priya Kim, Mahadi Baig, Paul L. Swiecicki
Amivantamab plus paclitaxel in recurrent/metastatic head & neck squamous cell cancer after disease progression on checkpoint inhibition: Identification of the recommended combination dose from the phase 1b/2 OrigAMI-4 study
Paul L. Swiecicki, Bhumsuk Keam, Shau-Hsuan Li, Varinder Kaur, Hung-Ming Wang, Douglas Adkins, Myung-Ju Ahn, Sung-Bae Kim, Aarti Bhatia, Missak Haigentz, Hsiang-Fong Kao, Ari J. Rosenberg, Chunying Gao, Joshua C. Curtin, Xuesong Lyu, Kiichiro Toyoizumi, Aastha Kapoor, Emrullah Yilmaz, Mahadi Baig, Muh-Hwa Yang
Association of Molecular Markers With Clinical Response to TAR-200 in the Phase 2b SunRISe-1 Trial in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) With Carcinoma in Situ (CIS), With or Without Papillary Disease
Felix Guerrero-Ramos, Siamak Daneshmand, Girish S. Kulkarni, Andrea Necchi, Giuseppe Simone, Martin Boegemann, Joseph Jacob, Shalaka Hampras, Hussein Sweiti, Abhijit Shukla, Jason Martin, Kate Stromberg, Jiarui Zhang, Karen Urtishak, Patricia Raciti, Shibu Thomas, Flavia Pinho, Joshua Meeks, Michiel S. van der Heijden
Association of somatic/germline homologous recombination repair (HRR) alterations with prostatespecific antigen, radiographic and second progression-free survival (PSA-PFS, rPFS and PFS2) in metastatic hormone-sensitive prostate cancer by disease volume
David Lorente, Daniel Tello Velasco, Ana Jambrina, Ignacio Gonzalez-Ginel, Nuria Romero-Laorden, Diogo Nunes-Carneiro, Casilda Llácer, Manual Balongo, Rocio Santos, David Hernández, Alexandra Jürgens, Camille Capone, Marco Trevisan, Suzy Van Sanden, Gabriel Stulnig, Pedro P. López-Casas, Daniel E. Castellano, Bernardo Herrera-Imbroda, David Olmos, Elena Castro
COPERNICUS: A multinational pragmatic phase 2 trial of subcutaneous amivantamab in common EGFR-mutated NSCLC
Balazs Halmos, Narjust Florez, Sarah Goldberg, Wade Iams, Xiuning Le, Ticiana Leal, Danny Nguyen, Luis Raez, Jonathan Riess, Joshua Sabari, David Bjork, Nichelle Stigger, Anna Minchom, Yichuan Xia, Paul Cifuentes, Farah Shanoon, James Penton, Annika Hultén, Melissa Johnson
Deep Learning-based Digital Pathology Algorithm Overcomes Tumor Content Limitations for FGFR Alteration Detection in Non-Muscle Invasive Bladder Cancer
Albert Juan Ramon, Chaitanya Parmar, Patricia Raciti, Neil Beeharry, Christopher J. Medberry, Cheng Zhang, Yaji Xu, David Weingeist, Kasha Dziuba, Guneet Walia, Nicole Stone, Spyros Triantos, Joel Greshock, Kristopher A. Standish
Efficacy of Niraparib and Abiraterone Acetate plus Prednisone in metastatic castration-resistant prostate cancer with HRR gene alterations identified by tissue vs plasma assay in MAGNITUDE study (final analysis)
Gerhardt Attard, Usha Singh, Victoria Zadorozhny, Yaji Xu, Lesley Farrington, Katie Bell, Daphne Wu, Sharon McCarthy, Fei Shen, Songbai Wang
Impact of Dose Reductions on the Efficacy of Erdafitinib in Patients with Advanced or Metastatic Urothelial Carcinoma: A Post-hoc Analysis of the Phase 3 THOR Study Cohort 1 Evaluating Erdafitinib Versus Chemotherapy
Patrizia Giannatempo, Arlene O. Siefker-Radtke, Robert A. Huddart, Nadine Houede, Severine Banek, Valentina Guadalupi, Begoña P. Valderrama, Sepideh Nemat, Jagadish Gogate, Qing Li, Bárbara Pinto, Mahmoud Abdelgawad, Yohann Loriot
Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab or cetrelimab alone in patients with muscle-invasive bladder cancer: SunRISe-4 primary analysis and biomarker results
Andrea Necchi, Felix Guerrero-Ramos, Paul L. Crispen, Bernardo Herrera-Imbroda, Rohan Garje, Bernadett Szabados, Charles C. Peyton, Benjamin Pradere, Ja Hyeon Ku, Neal Shore, Martin Bögemann, Mark A. Preston, Evanguelos Xylinas, Cristina Sanchez de Llano, Mohamad Hasan, Hind Stitou, Sumeet Bhanvadia, Hussein Sweiti, Sarah P. Psutka
PROMISE: Overview of therapeutic management and disease progression in patients with localized prostate cancer based on the French National Health Data System (SNDS)
Stéphane Supiot, Jean-Emmanuel Bibault, Alice Brouquet, Hélène Denis, Eleonore Herquelot, Baptiste Pitel, Pierre-Marie Touminet, Laurène Gautier, Thilina Kariyawasam, Bertrand Lukacs, Yann Neuzillet
Patient-Reported Outcomes From AMPLITUDE, a Randomized, Placebo-Controlled Phase 3 Trial of Niraparib and Abiraterone Acetate Plus Prednisone in Metastatic Hormone-Sensitive Prostate Cancer With Homologous Recombination Repair Mutations
Dana E. Rathkopf, Neeraj Agarwal, Julie N. Graff, Shahneen Sandhu, Eleni Efstathiou, Mustafa Özgüroğlu, Andrea J. Pereira de Santana Gomes, Karina Vianna, Hong Luo, Geoffrey T. Gotto, Heather H. Cheng Carly R. Varela, Katharine S. Gries, Benoit Baron, Fei Shen, Suneel D. Mundle, Sharon A. McCarthy, David Olmos, Kim N. Chi, Gerhardt Attard
Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination With Cetrelimab in Advanced Solid Tumors
Victor Moreno Garcia, Emiliano Calvo, Liza Villaruz, Enriqueta Felip, Rastislav Bahleda, Christopher Manley, Ester Garcia-Lorenzo, Ramon Yarza, Juan Jose Soto-Castillo, Aisha Hasan, Julia Billiard, Jorge Da Silva, Ariel Chen, Douglas Steinbach, Samantha Weber, Samaan Rafeq, Rajesh Bandekar, Stewart Bates, Roland Knoblauch, Sarina A. Piha-Paul
Prevalence and Severity of Hot Flashes and Their Association With Prostate-Specific Antigen Response: Results From the Initial Treatment Phase of LIBERTAS, a Phase 3 Study in Metastatic Hormone- Sensitive Prostate Cancer
Alicia K. Morgans, Arun A. Azad, Marco Antonio Badillo Santoyo, Qiang Dong, Dana E. Rathkopf, Karie Runcie, Tian Zhang, Geoffrey Gotto, Axel S. Merseburger, Alex Dos Santos, Sukie Shopeju, Amitabha Bhaumik, Simon Todd, Suneel D. Mundle, Sharon A. McCarthy, Mark Wildgust, Neeraj Agarwal
Real-World Use of Bacillus Calmette-Guérin (BCG) in Patients With High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)
Géraldine Pignot, Wassim Kassouf, Takashi Kobayashi, Nimira Alimohamed, Lucy Andersen, Sarah Côté, Ruhee Jain, Brendan Osborne, Marie Deault-Bonin, Siobhán Mulhern-Haughey, Jacob Skilling, Mia Unsworth, Laure Manuel, Emilia Biondi, Elliott Brown, Jonathan Aning
Real-World Utilization and Outcomes With PACIFIC Regimen in Stage III Unresectable Non-Small Cell Lung Cancer Patients: Results From a Multicenter US Database
Melina E. Marmarelis, Meijia Zhou, Sajjad Raza, Qing Huang, Kiran Devisetty, Balaji Laxmanan, Rachael L. DiSantostefano, Iftekhar Kalsekar, Daniel Gomez
Subcutaneous amivantamab plus chemotherapy in EGFR-mutant advanced non-small cell lung cancer after disease progression on osimertinib
Ernest Nadal, Joel W. Neal, Diego Signorelli, Jiunn Liang Tan, Vladimir De Lima, Ke-Jing Tang, Sarah Benafif, Mor Moskovitz, Akira Ono, Martin Reck, Sandrine Hiret, Saiama N. Waqar, Saugata Das, Ali Alhadab, Miao Wang, Janine Mahoney, Jie Zhang, Sujay Shah, Mahadi Baig, Sun Min Lim
Translational Analyses of T-Cell Phenotypes and Their Association With Clinical Efficacy in the First-In-Human (FIH) Trial of JNJ-78278343 (Pasritamig) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Karen Autio, Michael T. Schweizer, Kristin Shotts, Ruchi Chaudhary, Michael Brady, Sarah Casanova, Patricia Raciti, Mark N. Stein, Capucine Baldini
